

Company Overview

Veracyte is a global cancer diagnostics company. Our molecular tests assess the unique biology of each patient's tumor to help clinicians answer essential questions about cancer care. Through the Veracyte Diagnostics Platform, we take a comprehensive, whole-ome view of tumor biology with every test we perform, enabling us to support our partners' groundbreaking research and develop innovative tests that fill gaps in care. Our vision is to transform cancer care for patients around the world.



Fast Facts

>800K

Total patients served with our tests¹

>20

Countries served²

~800

Employees serving clinicians and patients worldwide²



Global offices in San Francisco, San Diego, Austin, and Haifa

2008

Year Veracyte was founded

>600

Peer-reviewed publications validate our platform's clinical utility³




Headquarters is located in South San Francisco, California

\$517.1M

2025 annual revenue

The Veracyte Diagnostics Platform



Unlocking a deeper understanding of cancer and fueling evidence generation

- **More data:** broad genomic assays and clinical data
- **More insights:** AI-assisted data mining
- **More proof:** robust and efficient evidence-generation engine
- **More utility:** differentiated market expansion approach

Recognition



Great Place To Work®
Certified™ U.S. and Israel

Forbes

Forbes' 2025 Most Successful
Mid-Cap Companies




Fortune Best Workplaces
in BioPharma™ 2025



veracyte.com

Portfolio Overview

Veracyte's expanding portfolio spans multiple cancer types and stages of care across the continuum, from diagnosis to recurrence monitoring.



Flagship Tests



Afirma® Genomic Sequencing Classifier

The Afirma test helps clinicians personalize thyroid cancer diagnosis and treatment decisions for their patients with thyroid nodules.

Diagnosis and prognosis



Decipher® Prostate Genomic Classifier

Decipher Prostate is a tissue-based molecular test used to assess risk of metastasis or metastatic progression in patients with localized or advanced prostate cancer.

Prognosis and treatment guidance



Decipher® Bladder Genomic Classifier

Decipher Bladder is a molecular subtyping tool that identifies patients who are more likely to progress, be upstaged, and benefit from certain therapies.

Prognosis and treatment guidance



Prosigna® Breast Risk of Recurrence Test

The Prosigna Breast Risk of Recurrence Test combines intrinsic molecular subtypes and proliferation score with clinical pathological factors into a single Risk of Recurrence (ROR) score. It also calculates the patient's 10-year risk of distant recurrence, and predicts whether they are likely to benefit from chemotherapy.

Prognosis and treatment guidance



TrueMRD™ Monitoring Test for MIBC

TrueMRD for MIBC uses whole-genome sequencing (WGS) to create a personalized, patient-specific tumor signature that detects ctDNA in blood to monitor for recurrence of muscle-invasive bladder cancer after definitive therapy.

Recurrence monitoring



The future of Veracyte

Explore our portfolio of market-leading molecular tests and pipeline innovations helping to transform cancer care for patients worldwide.



Contact Information



Corporate Headquarters:
6000 Shoreline Court, Suite 300
South San Francisco, CA 94080

Phone: +1-650-243-6300
Media: media@veracyte.com
Investors: investor@veracyte.com
Website: veracyte.com

[linkedin.com/company/veracyte](https://www.linkedin.com/company/veracyte)
 @Veracyte
 @Veracyte

1. Total patients served with any Veracyte test inception through December 31, 2025
2. Company data on file as of December 31, 2025
3. Total publications utilizing any Veracyte test from inception through December 31, 2025.

Afirma, Decipher, Prosigna and TrueMRD for MIBC testing is available in the United States as a laboratory developed test (LDT) service and has not been cleared or approved by the FDA.

©2026 Veracyte, Inc. The trademarks mentioned herein are the property of Veracyte (for a non-exhaustive list, see www.veracyte.com/trademarks) or their respective owners. VCTY.1.1.04.26



veracyte.com